Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 62
Filtrar
Mais filtros













Base de dados
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 98(47): e17968, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31764801

RESUMO

To identify the risk factors for destruction of large joints in the lower extremities in patients with rheumatoid arthritis (RA) during a 4-year follow-up period in a prospective study.We enrolled consecutive patients who participated in both 2012 and 2016. Clinical data, disease activity, and types of medication were collected in 2012. Standard anteroposterior radiographs of weight-bearing joints (hips, knees, and ankles) were taken in 2012 and 2016. Radiographic progression was defined as progression in the Larsen grade or the need for joint arthroplasty or arthrodesis. The association between baseline characteristics and the incidence of radiographic progression was statistically assessed.A total of 213 patient were enrolled, and, after exclusion, 186 patients were analyzed. Sixty 9 patients (37.1%) showed radiographic progression in 1 of the large joints in the lower extremities. Multivariate regression analysis showed that radiographic progression was associated with older age, higher disease activity, and the presence of radiographic destruction at the baseline. The lower dosage of oral prednisolone was a significant risk factor compared with higher dosage when used.Patients with the risk factors should be followed closely to limit the progression of large joint destruction in the lower extremities.


Assuntos
Articulação do Tornozelo/diagnóstico por imagem , Articulação do Tornozelo/patologia , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/patologia , Glucocorticoides/administração & dosagem , Articulação do Quadril/diagnóstico por imagem , Articulação do Quadril/patologia , Articulação do Joelho/diagnóstico por imagem , Articulação do Joelho/patologia , Prednisolona/administração & dosagem , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Radiografia , Fatores de Risco
2.
Arthritis Res Ther ; 21(1): 174, 2019 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-31307521

RESUMO

BACKGROUND: Rheumatoid arthritis (RA) is known to cause secondary osteoporosis and fragility fractures. This study aimed to identify biomarkers predictive of bone mineral density (BMD) change at three anatomical sites in patients with RA. METHODS: We conducted a prospective longitudinal study in patients with RA. In 2012, we recruited 379 patients from an RA cohort, 329 of whom underwent evaluation of blood and urine biomarkers together with measurement of BMD in the lumbar spine, proximal femur, and distal forearm. The BMD in these three regions was reassessed in 2014. We performed multivariate linear regression analysis to identify those factors associated with BMD change. RESULTS: The averages of age, body mass index, and disease activity score in 28 joints (DAS28) at baseline were 63.2 (minimum to maximum, 32-85), 21.3 (12.3-30.0), and 3.2 (0.1-5.9), respectively. Univariate analysis showed that the annual BMD change was significantly associated with the use of steroid, bisphosphonate (BP) or vitamin D (VitD), and serum homocysteine in the lumber spine; DAS28, the use of BP or VitD, CRP, and anti-cyclic citrullinated peptide antibody (ACPA) in the proximal femur; and the dosage of MTX, the use of BP or VitD, and serum tartrate-resistant acid phosphatase 5b (TRACP-5b) in the distal forearm, respectively. CONCLUSIONS: Predictive biomarkers for BMD change in RA patients differ at each anatomical site. Practitioners should treat each anatomical site with different markers and prescribe osteoporosis drugs to prevent fractures for RA patients.


Assuntos
Artrite Reumatoide/metabolismo , Biomarcadores/análise , Osso e Ossos/metabolismo , Osteoporose/metabolismo , Absorciometria de Fóton/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/tratamento farmacológico , Biomarcadores/sangue , Biomarcadores/urina , Densidade Óssea/efeitos dos fármacos , Conservadores da Densidade Óssea/uso terapêutico , Osso e Ossos/efeitos dos fármacos , Difosfonatos/uso terapêutico , Feminino , Fêmur/efeitos dos fármacos , Fêmur/metabolismo , Humanos , Estudos Longitudinais , Vértebras Lombares/efeitos dos fármacos , Vértebras Lombares/metabolismo , Masculino , Pessoa de Meia-Idade , Osteoporose/diagnóstico , Osteoporose/tratamento farmacológico , Estudos Prospectivos , Rádio (Anatomia)/efeitos dos fármacos , Rádio (Anatomia)/metabolismo , Ulna/efeitos dos fármacos , Ulna/metabolismo , Vitamina D/uso terapêutico
3.
Colorectal Dis ; 18(7): 696-702, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26748553

RESUMO

AIM: The study investigated the value of faecal lactoferrin as a follow-up biomarker for mucosal healing of ulcerative colitis during granulocyte and monocyte adsorptive apheresis (GMA) therapy. METHOD: Patients with ulcerative colitis exhibiting a moderate or severe disease activity with a partial Mayo Score (pMS) of over 4 were enrolled in this study. The patients received 10 courses of GMA therapy. The pMS value and faecal lactoferrin level were monitored and compared with the findings of endoscopy until 12 months after the last dose of GMA therapy. RESULTS: Twenty patients (male:female 11:9) were enrolled in this study. Twelve had total colitis, while six had left-sided involvement and two had distal proctitis. Thirteen (65.0%) responded to GMA therapy. The faecal lactoferrin levels were significantly decreased in patients who responded to GMA therapy (P < 0.05), whereas the levels did not change in non-responders. Moreover, the faecal lactoferrin levels correlated with the endoscopic findings (r = 0.792, P < 0.01) and pMS scores (r = 0.529, P < 0.01). The correlation coefficients between the faecal lactoferrin levels and mucosal findings were higher than those observed between the pMS score and mucosal findings. CONCLUSION: The faecal lactoferrin level is a useful biomarker of the mucosal findings in ulcerative colitis. Although endoscopy is the gold standard, the faecal lactoferrin level can be used as a biomarker during GMA therapy in patients with ulcerative colitis.


Assuntos
Colite Ulcerativa/terapia , Fezes/química , Mucosa Intestinal/patologia , Lactoferrina/análise , Leucaférese/métodos , Adulto , Idoso , Biomarcadores/análise , Colite Ulcerativa/patologia , Feminino , Granulócitos , Humanos , Masculino , Pessoa de Meia-Idade , Monócitos , Resultado do Tratamento , Adulto Jovem
4.
J Clin Pharm Ther ; 38(1): 74-6, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22971159

RESUMO

WHAT IS KNOWN AND OBJECTIVE: Both itraconazole (ITCZ) and voriconazole (VCZ) are potent inhibitors of cytochrome P450 (CYP) 3A, and their effects have been reported to be equal. However, ITCZ is metabolized by CYP3A, whereas VCZ is mainly metabolized by CYP2C9 and CYP2C19 and only partially by CYP3A. We experienced the case of a patient who showed a 5-fold increase in trough levels of tacrolimus (FK) level after switching from ITCZ to VCZ. Our objective is to discuss the mechanism of the increase drug-drug interaction in terms of serum concentration of the azole drugs and patient pharmacogenomics. CASE SUMMARY: A 53-year-old woman was treated with FK (1 mg/day) for lupus nephritis. Because fungal infection was suspected, she received ITCZ (100 mg/day). When ITCZ was replaced with VCZ (400 mg/day), the blood concentration of FK increased markedly from 6·1 to 34·2 ng/mL. During coadministration with FK, the levels of ITCZ and VCZ were 135·5 ng/mL and 5·5 µg/mL, respectively, with the VCZ level around 3-fold higher than the previously reported level (1·4-1·8 µg/mL). Her CYP genotypes were CYP2C19*1/*2, CYP3A4*1/*1 and CYP3A5*3/*3. WHAT IS NEW AND CONCLUSION: The patient was a CYP2C19 intermediate metabolizer (IM) and deficient in CYP3A5. The increase in plasma VCZ level appears to have been at least in part, associated with the CYP2C19 IM phenotype. One possible explanation for the marked increase in blood FK concentration was increased inhibition of CYP3A because of the impaired metabolism and subsequent increased plasma concentration of VCZ. This case shows that the severity of drug interactions may be influenced by metabolic gene polymorphism.


Assuntos
Antifúngicos/farmacocinética , Imunossupressores/farmacocinética , Nefrite Lúpica/tratamento farmacológico , Tacrolimo/farmacocinética , Antifúngicos/farmacologia , Hidrocarboneto de Aril Hidroxilases/genética , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP3A/genética , Interações Medicamentosas , Feminino , Genótipo , Humanos , Imunossupressores/uso terapêutico , Itraconazol/farmacocinética , Itraconazol/farmacologia , Pessoa de Meia-Idade , Farmacogenética , Polimorfismo Genético , Pirimidinas/farmacocinética , Pirimidinas/farmacologia , Tacrolimo/uso terapêutico , Triazóis/farmacocinética , Triazóis/farmacologia , Voriconazol
5.
Intern Med ; 40(4): 320-3, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11334392

RESUMO

A 72-year-old man with diabetic triopathy was hospitalized with methicillin resistant staphylococcus aureus pneumonia. Six hours after the admission, his abdomen was fully expanded. An abdominal X-ray showed gastric dilatation. After insertion of a gastric tube to extract gastric air, his abdomen was flat and gastric dilatation improved. A positive Schellong test and decreased coefficient of RR interval in electrocardiogram variation indicated autonomic neuropathy, which may explain the reason for gastric hypomotility. Acute gastric dilatation in this patient may have occurred due to gastric hypomotility as a result of diabetic autonomic neuropathy in addition to gastric motility inhibition resulting from gastric autonomic nerve stimulation by bacterial toxin.


Assuntos
Neuropatias Diabéticas/fisiopatologia , Dilatação Gástrica/complicações , Doença Aguda , Idoso , Nefropatias Diabéticas/fisiopatologia , Neuropatias Diabéticas/complicações , Retinopatia Diabética/fisiopatologia , Dilatação Gástrica/diagnóstico por imagem , Dilatação Gástrica/terapia , Motilidade Gastrointestinal , Humanos , Intubação Gastrointestinal , Masculino , Radiografia
6.
Diabetes Res Clin Pract ; 51(1): 39-43, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11137180

RESUMO

A 67-year-old woman with diabetes mellitus was hospitalized due to a throbbing headache. She appeared neurologically normal, except for meningeal irritation. The cerebrospinal fluid pressure was high. There was increased fluid protein without an increased cell count. Brain CT scan showed no abnormality, however, brain magnetic resonance angiography (MRA) showed complete right transverse sinus stasis and partial left transverse sinus stasis, indicating bilateral transverse sinus thrombosis. At this time thrombin anti-thrombin III complex (TAT) and prothrombin fragment F1+2 (PTF1+2) indicating hypercoagulation had increased. Urokinase, followed by aspirin and ticlopidine hydrochloride were administered. After diet therapy and transient insulin administration, her blood glucose levels improved. By the 22nd day, the headache had disappeared. Subsequently, brain MRA showed left transverse sinus blood flow recovery and complete right transverse sinus stasis, while carotid angiography showed recovered left transverse sinus but right transverse sinus defect. TAT and PTF1+2 levels improved concomitantly with better blood glucose control. We diagnosed this case as left transverse sinus thrombosis because of the hypercoagulable state resulting from diabetes mellitus accompanied by right transverse sinus aplasia.


Assuntos
Cavidades Cranianas/anormalidades , Diabetes Mellitus Tipo 2/complicações , Angiopatias Diabéticas/diagnóstico , Trombose dos Seios Intracranianos/diagnóstico , Idoso , Aspirina/uso terapêutico , Angiografia Cerebral , Cavidades Cranianas/patologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Angiopatias Diabéticas/tratamento farmacológico , Dieta para Diabéticos , Feminino , Fibrinolíticos/uso terapêutico , Cefaleia , Humanos , Angiografia por Ressonância Magnética , Imageamento por Ressonância Magnética , Metformina/uso terapêutico , Trombose dos Seios Intracranianos/tratamento farmacológico , Ticlopidina/uso terapêutico , Tomografia Computadorizada por Raios X , Ativador de Plasminogênio Tipo Uroquinase/uso terapêutico
7.
Int Surg ; 86(2): 135-7, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11918240

RESUMO

This report illustrates the case of a 79-year-old woman in whom a severe type of rectus sheath hematoma was found during conservative therapy for myocardial infarction. Although establishing a correct diagnosis and initiating conservative therapy is usually considered the most appropriate management of this clinical entity, the rectus sheath hematoma in this patient required surgical treatment.


Assuntos
Hematoma/cirurgia , Doenças Musculares/cirurgia , Músculos Abdominais , Idoso , Evolução Fatal , Feminino , Hematoma/diagnóstico , Humanos , Doenças Musculares/diagnóstico
8.
Diabetes Res Clin Pract ; 48(2): 99-104, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10802146

RESUMO

A 72-year-old woman with diabetic nephropathy was hospitalized with peripheral edema in the extremities and weight increase. After diuretics and human serum albumin administration, her condition improved. From the 15th day she had run a subfever and her breathing was diminished in the left lower lung field. A plain chest X-ray film showed pleural effusion over the left lung field. The fluid was exudative. Fluid cultures were negative. A tuberculin reaction was negative. Polymerase chain reaction method disclosed mycobacterium avium complex, indicating rare pleuritis due to mycobacterium avium complex. Eighteen days after chemotherapy, pleural effusion disappeared. Although her hemoglobin A1c (HbA1c) levels were maintained from 6.0 to 6.5% over 4 years, urinary albumin excretion levels and serum creatinine levels increased, indicating deteriorating diabetic nephropathy. Serum albumin levels remained low (3.3-3.6 g/dl). Malnutrition, impaired cellular immunity and apparently abnormal microvascular circulation due to diabetes mellitus may consequently have induced pleuritis due to mycobacterium avium complex.


Assuntos
Diabetes Mellitus Tipo 2/complicações , Infecção por Mycobacterium avium-intracellulare/diagnóstico , Pleurisia/microbiologia , Idoso , Antituberculosos/uso terapêutico , Cardiomegalia/diagnóstico por imagem , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/urina , Nefropatias Diabéticas/complicações , Feminino , Humanos , Complexo Mycobacterium avium/isolamento & purificação , Infecção por Mycobacterium avium-intracellulare/complicações , Infecção por Mycobacterium avium-intracellulare/tratamento farmacológico , Pleurisia/diagnóstico por imagem , Pleurisia/etiologia , Radiografia Torácica
9.
J Atheroscler Thromb ; 7(2): 91-6, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11426588

RESUMO

Lipid abnormalities in diabetic patients, particularly in those with nephropathy, may be partially due to deteriorating atherosclerosis. Therefore, strict control of the lipid metabolism in addition to glycemic control is desirable. Whether or not lipid lowering drugs prevent albuminuria in diabetic patients in the long term remains unclear. This study involved 71 NIDDM patients with hypercholesterolemia (group A: n = 37, group B: N = 34). The effect of bezafibrate (group A) or pravastatin (group B) on the cholesterol (CH) content of apolipoprotein AI, B100 containing particles or remnant-like particles (RLP) or urinary albumin excretion was studied over 4 years. The CH content in apolipoprotein B100 particles after treatment with either bezafibrate or pravastatin decreased significantly (group A: 24.7%, group B: 26.6%). The CH content in RLP after treatment with bezafibrate showed a significant decrease (67.9%). Apolipoprotein AI after treatment with bezafibrate showed a significant increase (10.9%). Apolipoprotein B100 after treatment with either drug decreased significantly (group A: 19.8%, group B: 23.4%). The urinary albumin excretion rate after treatment with either drug showed no significant change over 4 years. Bezafibrate and pravastatin appear to be useful in the preventive treatment of albuminuria as well as in lowering lipid levels in NIDDM patients.


Assuntos
Albuminúria/sangue , Bezafibrato/uso terapêutico , Diabetes Mellitus Tipo 2/sangue , Hipolipemiantes/uso terapêutico , Lipídeos/sangue , Pravastatina/uso terapêutico , Albuminúria/tratamento farmacológico , Apolipoproteína A-I/sangue , Apolipoproteína A-I/efeitos dos fármacos , Apolipoproteína B-100 , Apolipoproteínas B/sangue , Apolipoproteínas B/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Estudos de Casos e Controles , Colesterol/sangue , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Retinopatia Diabética/tratamento farmacológico , Retinopatia Diabética/etiologia , Humanos , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/etiologia , Insulina/sangue , Masculino , Pessoa de Meia-Idade
10.
Jpn Circ J ; 63(4): 323-5, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10475784

RESUMO

Sustained monomorphic ventricular tachycardia (VT) developed in a 58-year-old man with acute myocardial infarction and end-stage renal disease. Amiodarone was effective in preventing VT recurrence. Sustained VT was not induced during an electrophysiologic study. However, VT recurred during accidental hyperkalemia, which was caused by the change of dialysis therapy from peritoneal dialysis to hemodialysis. VT subsided with correction of hyperkalemia. Thereafter, VT did not recur as long as the serum potassium concentration was kept within the normal range. Several months later, the patient died suddenly because poor dietary compliance resulted in an increase in his potassium concentration. This case suggests that hyperkalemia may reverse the potent antiarrhythmic effects of amiodarone.


Assuntos
Amiodarona/farmacologia , Antiarrítmicos/farmacologia , Hiperpotassemia , Taquicardia Ventricular/tratamento farmacológico , Taquicardia Ventricular/metabolismo , Injúria Renal Aguda/complicações , Injúria Renal Aguda/metabolismo , Amiodarona/uso terapêutico , Antiarrítmicos/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/complicações , Infarto do Miocárdio/metabolismo , Taquicardia Ventricular/etiologia
11.
Am J Kidney Dis ; 32(5): 725-30, 1998 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9820440

RESUMO

We studied the relationship between polymorphism in intron 16 of the angiotensin-converting enzyme (ACE) gene and left ventricular (LV) hypertrophy in uremic patients treated with hemodialysis therapy. The LV parameters were not different for age-, hematocrit-, and blood pressure-matched patients in DD, ID, and II genotype groups. The most important factor for LV hypertrophy was systolic blood pressure, which correlated with the posterior wall thickness (r=0.35; P=0.001) and LV mass index (LVMI; r=0.23; P=0.032). Among nonhypertensive patients, the frequency of interventricular septum (IVS) hypertrophy (>12 mm) and hypertrophy in LVMI (>145 g/m2) was significantly greater in patients with the DD genotype than in I allele-positive (+) patients. The odds rate for IVS hypertrophy was 5.04 (95% confidence interval, 1.15 to 24.8). These data suggest that the DD genotype of the ACE gene polymorphism is a contributory factor for the development of LV hypertrophy in patients with end-stage renal disease (ESRD).


Assuntos
Deleção de Genes , Hipertrofia Ventricular Esquerda/genética , Íntrons/genética , Falência Renal Crônica/genética , Mutagênese Insercional , Peptidil Dipeptidase A/genética , Polimorfismo Genético/genética , Fatores Etários , Alelos , Pressão Sanguínea , Estudos de Casos e Controles , Intervalos de Confiança , Ecocardiografia , Feminino , Genótipo , Septos Cardíacos/diagnóstico por imagem , Septos Cardíacos/patologia , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/patologia , Hematócrito , Humanos , Hipertrofia Ventricular Esquerda/diagnóstico por imagem , Hipertrofia Ventricular Esquerda/enzimologia , Hipertrofia Ventricular Esquerda/patologia , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Razão de Chances , Diálise Renal , Uremia/genética , Uremia/terapia
12.
Intern Med ; 37(5): 454-6, 1998 May.
Artigo em Inglês | MEDLINE | ID: mdl-9652900

RESUMO

A 70-year-old man with diabetic triopathy was hospitalized with left lower quadrant abdominal pain and tenderness, muscle guarding and absent bowel sounds. Three hours after admission, creatine phosphokinase (CPK) was elevated and an abdominal plain film X-ray showed intestinal gas retention, indicating paralytic ileus due to inferior mesenteric artery occlusion. Urokinase (60,000 units/day) and heparin (10,000 units/day) were administered. Angiography showed no occlusion in the mesenteric artery. On the 16th day, the abdominal signs had disappeared and CPK was normalized. We diagnosed this case as nonocclusive colonic ischemia because of the hemorheological abnormalities due to diabetic triopathy and the hypercoagulable state.


Assuntos
Colite Isquêmica/etiologia , Diabetes Mellitus Tipo 2/complicações , Idoso , Angiografia , Anticoagulantes/uso terapêutico , Colite Isquêmica/diagnóstico por imagem , Colite Isquêmica/tratamento farmacológico , Quimioterapia Combinada , Seguimentos , Heparina/uso terapêutico , Humanos , Masculino , Ativadores de Plasminogênio/uso terapêutico , Ativador de Plasminogênio Tipo Uroquinase/uso terapêutico
13.
Intern Med ; 37(12): 1039-41, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9932637

RESUMO

A 21 -year-old man with Prader-Willi syndrome (PWS) was hospitalized due to hyperglycemia. After diet therapy and transient insulin administration, his blood glucose levels improved. Based on the fact that his urinary C-peptide levels increased, the diabetes mellitus may have been due to insulin resistance with obesity. In addition, his testes had become atrophied. Testosterone levels remained low even after human chorionic gonadotropin (HCG) administration. Luteinizing hormone (LH) levels were also low after LH releasing hormone (LHRH) administration. The LH response increased slightly after daily LHRH administration, indicating hypothalamic hypogonadism. Follicle stimulating hormone (FSH) levels were, however, high and increased after LHRH administration. The selective FSH elevation may have been due to the accompanying idiopathic oligospermia.


Assuntos
Diabetes Mellitus Tipo 1/complicações , Hormônio Foliculoestimulante/sangue , Síndrome de Prader-Willi/sangue , Adulto , Glicemia/metabolismo , Peptídeo C/sangue , Gonadotropina Coriônica/administração & dosagem , Gonadotropina Coriônica/uso terapêutico , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/tratamento farmacológico , Seguimentos , Moduladores GABAérgicos/administração & dosagem , Moduladores GABAérgicos/uso terapêutico , Hormônio Liberador de Gonadotropina/administração & dosagem , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Injeções Intravenosas , Insulina/administração & dosagem , Insulina/uso terapêutico , Hormônio Luteinizante/sangue , Masculino , Síndrome de Prader-Willi/complicações , Síndrome de Prader-Willi/tratamento farmacológico , Radioimunoensaio , Testosterona/sangue
14.
J Atheroscler Thromb ; 5(2): 54-9, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-10855558

RESUMO

We investigated the effect of nephropathy on the composition of apolipoprotein-containing particles in non-obese NIDDM patients with normocholesterolemia. Sixty-seven normal control subjects (group A), 48 NIDDM patients without nephropathy (group B) and 36 NIDDM patients with nephropathy (group C) were studied. Apolipoprotein AI or B100 containing particles (Apo AI or Apo B100) were isolated by immunoaffinity columns prepared with monoclonal antibodies. The total cholesterol (CH), esterified cholesterol (EC) and free cholesterol (FC) content in these particles was analyzed. Both the EC/FC ratio levels in Apo AI and in Apo B100 in group C were significantly higher than those in group A or B. Both the CH in Apo AI/apolipoprotein AI ratio and in Apo B100/apolipoprotein B100 ratio levels in group C were significantly lower than those in group A or B. The insulin resistance index showed significant positive correlation with the EC/FC ratio levels in Apo AI and in Apo B100, and showed significant negative correlation with the CH levels in Apo AI/apolipoprotein AI ratio and the CH levels in Apo B100/apolipoprotein B100 ratio levels in group C. Those compositional changes of lipoproteins in NIDDM patients with nephropathy may reflect partial insulin resistance and deteriorating atherosclerosis.


Assuntos
Apolipoproteínas/química , Diabetes Mellitus Tipo 2/sangue , Nefropatias Diabéticas/sangue , Anticorpos Monoclonais , Apolipoproteína A-I/sangue , Apolipoproteína A-I/química , Apolipoproteína A-I/imunologia , Apolipoproteína B-100 , Apolipoproteínas/sangue , Apolipoproteínas/imunologia , Apolipoproteínas B/sangue , Apolipoproteínas B/química , Apolipoproteínas B/imunologia , Glicemia/análise , Estudos de Casos e Controles , HDL-Colesterol/sangue , Cromatografia de Afinidade/métodos , Diabetes Mellitus Tipo 2/complicações , Nefropatias Diabéticas/complicações , Feminino , Humanos , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , Valores de Referência
15.
Intern Med ; 36(8): 575-8, 1997 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9260776

RESUMO

A 63-year-old insulin-dependent diabetic woman was hospitalized with itchy skin wheals at the injection sites of human insulin. After intradermal skin testing was performed, the erythema and wheal was recorded immediately. The increased titer of human insulin-specific IgE antibody indicated immediate-type allergy against human insulin. Administration of an anti-allergic drug or desensitization for human insulin every 2 hours was not effective. After continuous subcutaneous insulin infusion (CSII) therapy was performed, both the itching and wheal disappeared. The process may be a desensitization through CSII. CSII may be useful in the treatment for human insulin allergy.


Assuntos
Hipersensibilidade Imediata/tratamento farmacológico , Insulina/administração & dosagem , Insulina/efeitos adversos , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/imunologia , Hipersensibilidade a Drogas/tratamento farmacológico , Hipersensibilidade a Drogas/imunologia , Feminino , Humanos , Infusões Parenterais , Injeções Subcutâneas , Insulina/imunologia , Testes Intradérmicos , Pessoa de Meia-Idade
16.
Jpn J Antibiot ; 49(12): 1085-94, 1996 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-9032595

RESUMO

An investigation was carried out to determine whether or not here had been any changes in the susceptibility of clinically isolated strains of Trichophyton metagrophytes and Trichophyton rubrum (both leading causes of tinea) to bifonazole, an imidazole derivative and antifungal for topical use. Susceptibility was measured in 107 strains of these fungi isolated from clinical samples during a study on the treatment of tinea pedis with Mycospor cream in 1995, 42 strains isolated and stored in 1990, and 39 strains isolated and stored prior to development of the drug. The results are as follows: (1) There was no distinct difference in the susceptibility to bifonazole of T. mentagrophytes strains isolated before 1986 and those isolated in 1990 or 1995. (2) T. rubrum strains isolated before 1986 were slightly more susceptible to bifonazole than those isolated in 1995, while the 1990 strains were slightly less susceptible than the 1995 strains, but the difference was not significant. (3) The highest MICs of bifonazole for all the T. mentagrophytes and T. rubrum strains isolated from before 1986 and those in 1995 were relatively low, being 2.5 micrograms/ml and 1.25 micrograms/ml, respectively. These results suggest that no resistance or reduced susceptibility to bifonazole has emerged among clinical isolates of dermatophytes since the development of the drug.


Assuntos
Antifúngicos/farmacologia , Imidazóis/farmacologia , Tinha dos Pés/microbiologia , Trichophyton/efeitos dos fármacos , Clotrimazol/farmacologia , Resistência Microbiana a Medicamentos , Humanos , Fatores de Tempo , Trichophyton/isolamento & purificação
17.
Jpn J Antibiot ; 49(12): 1095-108, 1996 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-9032596

RESUMO

The usefulness of bifonazole (Mycospor), a topical imidazole antifungal agent approved 10 years ago, was evaluated for the treatment of tinea pedis. Mycospor cream was applied by 141 patients with tinea pedis once daily for 4 233ks, and the clinical efficacy and adverse reactions (as well as any correlations with susceptibility of isolates and the mycological activity of the agent against these isolates) were studied. The results were then compared to those of a previous study. The following results were obtained. 1. Mycological activity Mycological examination results became negative in 63.2% (36/57) of the patients with plantar tinea pedis, in 94.1% (32/34) of those with interdigital tinea pedis, and in 74.7% (68/91) of all tinea pedis patients. 2. Mycological activity and MIC No correlation was found between the MICs of bifonazole against the pathogenic fungi and the rate of eradication on mycological examination. 3. Improvement of symptoms The improvement rates for local symptoms were 82.5% for plantar tinea pedis, 85.7% for interdigital tinea pedis, and 83.7% for all tinea pedis. 4. Clinical efficacy Good clinical efficacies were found in 61.4% of the patients with plantar tinea pedis, in 88.6% of those with interdigital tinea pedis, and in 71.7% of all patients. 5. Safety Regarding adverse reactions, what seemed to be contact dermatitis was reported in 5 out of 127 cases (3.9%). The reaction decreased or disappeared in all cases. 6. Usefulness Mycospor was found to be useful in 64.9% of patients with plantar tinea pedis, in 88.6% of those with interdigital tinea pedis, and in 73.9% of all tinea pedis patients. 7. Comparison with former results The results obtained in the present clinical study were comparable to those obtained in patients with tinea pedis treated in a double-blind comparative study conducted during the development of as a new topical antifungal agent. From the above results, Mycospor cream was confirmed to be still useful, although it has been used widely for the topical treatment of cutaneous mycoses in the past 10 years since its approval.


Assuntos
Antifúngicos/uso terapêutico , Imidazóis/uso terapêutico , Tinha dos Pés/tratamento farmacológico , Adulto , Idoso , Resistência Microbiana a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tinha dos Pés/microbiologia , Trichophyton/efeitos dos fármacos , Trichophyton/isolamento & purificação
18.
Intern Med ; 35(5): 388-91, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8797053

RESUMO

A 41-year-old woman and her 2 sons had Type V hyperlipoproteinemia. Interestingly, the patient and her younger son had higher levels of remnant-like particle (RLP)-cholesterol than her elder son; the former two had apolipoprotein E phenotype E3/E4, while the latter had E3/E3. Hyper-RLP-ch levels may be associated with the apolipoprotein E4 phenotype. Moreover, after administration of bezafibrate, the patient's triglyceride, RLP-cholesterol and RLP-triglyceride levels decreased markedly and the chylomicron fraction disappeared. Further studies may be necessary to determine if hypertriglyceridemic patients with or without apolipoprotein E4 show a greater reduction in serum TG levels with lipid-lowering agents.


Assuntos
Apolipoproteínas E/genética , Colesterol/sangue , Quilomícrons/sangue , Hiperlipoproteinemia Tipo V/sangue , Lipoproteínas VLDL/sangue , Adulto , Apolipoproteína E3 , Apolipoproteína E4 , Apolipoproteínas E/sangue , Bezafibrato/uso terapêutico , Colesterol/química , Feminino , Heparina , Humanos , Hiperlipoproteinemia Tipo V/tratamento farmacológico , Hiperlipoproteinemia Tipo V/genética , Hipolipemiantes/uso terapêutico , Lipase/sangue , Lipase Lipoproteica/sangue , Masculino , Fenótipo , Triglicerídeos/sangue
19.
Diabetes Care ; 19(4): 365-8, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8729161

RESUMO

OBJECTIVE: Through analysis of apolipoprotein-containing particles after glucose ingestion, we determined abnormal lipid metabolism in NIDDM patients and subjects with impaired glucose tolerance (IGT) without obesity or hyperlipidemia. RESEARCH DESIGN AND METHODS: Apolipoprotein (apo) AI- or B100-containing particles or remnant-like particles (RLPs) were isolated by immunoaffinity columns prepared with monoclonal antibodies. The cholesterol contents in these particles after glucose ingestion (0, 30, 60, and 120 min) were analyzed in 18 nonobese NIDDM patients, 18 nonobese IGT subjects, and 33 normal control subjects. RESULTS: Changes in cholesterol content in apo B100 particles after oral glucose ingestion decreased significantly in both the NIDDM group and the IGT group; the changes were insignificant in the nondiabetic group. Changes in cholesterol content in the apo AI particles after oral glucose ingestion showed no differences between the three groups. Changes in cholesterol content in RLPs after oral glucose ingestion increased significantly in both the NIDDM group and IGT group; the changes were insignificant in the nondiabetic group. The changes in apo B100 after oral glucose ingestion decreased significantly in the three groups; however, apo AI after oral glucose ingestion showed no change in the three groups. CONCLUSIONS: The cholesterol content in apo B100 particles might decrease and the cholesterol content in RLPs might increase after oral glucose ingestion in not only NIDDM patients but also IGT subjects. The changes may be partially due to insulin resistance.


Assuntos
Apolipoproteína A-I/sangue , Apolipoproteínas B/sangue , Colesterol/sangue , Diabetes Mellitus Tipo 2/sangue , Carboidratos da Dieta , Intolerância à Glucose/sangue , Glucose , Apolipoproteína B-100 , Humanos , Insulina/sangue , Pessoa de Meia-Idade , Valores de Referência , Fatores de Tempo , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA